Skip to main navigation Skip to search Skip to main content

Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2–4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials

  • Marco Bandini
  • , Alberto Briganti
  • , Elizabeth R. Plimack
  • , Günter Niegisch
  • , Evan Y. Yu
  • , Aristotelis Bamias
  • , Neeraj Agarwal
  • , Srikala S. Sridhar
  • , Cora N. Sternberg
  • , Ulka Vaishampayan
  • , Christine Théodore
  • , Jonathan E. Rosenberg
  • , Joaquim Bellmunt
  • , Matthew D. Galsky
  • , Francesco Montorsi
  • , Andrea Necchi
  • Vita-Salute San Raffaele University
  • Heinrich Heine University Düsseldorf
  • University of Washington
  • National and Kapodistrian University of Athens
  • University of Utah
  • Princess Margaret Cancer Centre
  • San Camillo Hospital
  • Wayne State University
  • Hôpital Foch
  • Memorial Sloan-Kettering Cancer Center
  • Harvard University
  • Icahn School of Medicine at Mount Sinai
  • Fondazione IRCCS Istituto Nazionale dei Tumori

Research output: Contribution to journalArticlepeer-review

12 Scopus citations

Fingerprint

Dive into the research topics of 'Modeling 1-year Relapse-free Survival After Neoadjuvant Chemotherapy and Radical Cystectomy in Patients with Clinical T2–4N0M0 Urothelial Bladder Carcinoma: Endpoints for Phase 2 Trials'. Together they form a unique fingerprint.
Sort by

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science